Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO

Joaquín Martínez
Joaquín Martínez Jefe de Unidad de Investigación Clínica
T +34 917328000 (Ext )
jmartinezl@ext.cnio.es

Investigadores Científicos

  • Lucia Virginia Fernández
  • Miguel Gallardo
  • María Linares
  • Juan Manuel Rosa
  • María Velasco

Investigador Clínico I

  • Rosa María Ayala
  • María Calbacho
  • Gonzalo Carreño
  • María Pilar Carreras
  • María Teresa Cedena
  • Francisco Javier De La Serna
  • Ana Jiménez
  • María Inmaculada Rapado
  • Antonia Rodríguez
  • Ricardo Sánchez

Becarios Post-doctorales

  • Almudena García
  • Larissa Anita Haertle
  • Alejandra Leivas
  • Ana Rodríguez
  • Yanira Ruiz
  • Antonio Valeri

Becarios Pre-Doctorales

  • Noemí Álvarez
  • María Elena Barba
  • Pablo Blanco
  • Laura Córdoba
  • Jessica Encinas
  • Roberto García
  • Marta Ibáñez
  • Elena Maroto
  • Michael Ochieng
  • María Alejandra Ortiz
  • Álvaro Otero
  • Alba Rodríguez
  • Laura Sánchez

Técnicos de Laboratorio

  • Pedro Aguilar
  • Raquel Ancos
  • Andrés Arroyo
  • Irene Bragado
  • Natalia Sofía Buenache
  • Eva Castellano
  • Sara Dorado
  • Adrián Fernández
  • Vanesa Garrido
  • Alicia Giménez
  • María Luz Morales
  • Laura Moreno
  • Miguel Ángel Navarro
  • Irene Ortega
  • Laura Rufián
  • Daniel Valdés

Haematological clinical research has traditionally focused on haematological malignancies, aplasia and syndromes. Now, with advances in immunotherapy, haematologists play a key role in research on novel immunotherapeutic approaches, the role of the immune response to tumours, or the role of infection and inflammation in cancer.

In the Haematological Malignancies Clinical Research Unit at CNIO we investigate:

  • Traditional haematological neoplasms (leukaemia, myeloma, lymphoma): new diagnostic approaches, biomarkers, and treatments.
  • Aplastic haematological malignancies such as bone marrow failures: new drivers and molecular mechanisms.
  • Novel diagnosis and tumour burden monitoring: liquid biopsy and minimal residual disease.
  • Role of inflammation and infection in haematological neoplasms.
  • Novel immunotherapeutic approaches in haematological malignancies: NK-CARs, BITES.
  • Traditional immunotherapeutic approaches in haematological malignancies and paediatric cancers: T-CARs and immune checkpoints inhibitors.

Publicaciones

Subir